Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorasidenib - Servier

Next Previous
Drug Profile

Vorasidenib - Servier

Alternative Names: AG-881; AG-881 citrate; AG-881 hemicitrate; AGI-0023088; AGI-23088; S-95032; S095032; VORANIGO; Vorasidenib citrate; Vorasidenib hemicitrate hemihydrate

Latest Information Update: 05 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Servier
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Diamines; Fluorocarbons; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glioma
  • Registered Astrocytoma; Oligodendroglioma
  • Phase I Solid tumours
  • Discontinued Haematological malignancies

Most Recent Events

  • 28 Jan 2025 Phase-I/II clinical trials in Glioma (Combination therapy, In adolescents, In adults, In the elderly) in USA (PO) (NCT06478212)
  • 17 Jan 2025 Servier initiates enrolment in the phase III clinical trials in Glioma (First-line therapy, Recurrent, In children, In adolescents, In adults, In the elderly) in Japan (PO) (NCT06780930)
  • 26 Dec 2024 Chemical structure information updated.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top